company background image
VVY

Vivoryon Therapeutics ENXTAM:VVY Stock Report

Last Price

€8.58

Market Cap

€189.2m

7D

7.2%

1Y

-57.0%

Updated

16 Aug, 2022

Data

Company Financials +
VVY fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance0/6
Financial Health5/6
Dividends0/6

VVY Stock Overview

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer’s disease.

Vivoryon Therapeutics N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vivoryon Therapeutics
Historical stock prices
Current Share Price€8.58
52 Week High€22.58
52 Week Low€6.82
Beta1.99
1 Month Change22.92%
3 Month Change-1.15%
1 Year Change-57.02%
3 Year Change31.60%
5 Year Change-42.80%
Change since IPO-57.10%

Recent News & Updates

Shareholder Returns

VVYNL BiotechsNL Market
7D7.2%2.3%2.9%
1Y-57.0%-14.1%-13.4%

Return vs Industry: VVY underperformed the Dutch Biotechs industry which returned -13.1% over the past year.

Return vs Market: VVY underperformed the Dutch Market which returned -13.7% over the past year.

Price Volatility

Is VVY's price volatile compared to industry and market?
VVY volatility
VVY Average Weekly Movement10.3%
Biotechs Industry Average Movement8.1%
Market Average Movement4.9%
10% most volatile stocks in NL Market8.0%
10% least volatile stocks in NL Market2.9%

Stable Share Price: VVY is more volatile than 90% of Dutch stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: VVY's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Dutch stocks.

About the Company

FoundedEmployeesCEOWebsite
199715Ulrich Dauerhttps://www.vivoryon.com

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer’s disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease; and for the treatment of cancer.

Vivoryon Therapeutics N.V. Fundamentals Summary

How do Vivoryon Therapeutics's earnings and revenue compare to its market cap?
VVY fundamental statistics
Market Cap€189.19m
Earnings (TTM)-€12.65m
Revenue (TTM)€10.76m

17.6x

P/S Ratio

-15.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VVY income statement (TTM)
Revenue€10.76m
Cost of Revenue€1.57m
Gross Profit€9.20m
Other Expenses€21.85m
Earnings-€12.65m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.57
Gross Margin85.42%
Net Profit Margin-117.57%
Debt/Equity Ratio0%

How did VVY perform over the long term?

See historical performance and comparison